After publishing The Diagnostics Reimbursement Compass: A 90-Minute Guide to Define, Demonstrate and Capture Diagnostics Value Confidently we have also created some short “explainer” videos.
Check out: #4 – How to demonstrate diagnostics medical & economic value?
Diagnostics’ value is relative and very much context specific. It depends on the impacted stakeholders, the patient population in which the test is being applied, alternative solutions that are being compared with, and its indirect impact on the broader care pathway.
Diagnostics indirectly influence clinical, emotional, social, cognitive and behavioral patient outcomes. They also impact healthcare resource use and may result in workflow benefits that drive associated costs.
The clinical impact of a diagnostic test is characterized by analytical validity, clinical validity, and clinical utility. Clinical and economic evidence generation is usually in alignment with the test’s associated patient’s risks, its novelty, and healthcare providers’ familiarity with the product. The newer and riskier the test, the more clinical and economic evidence is required.
Economic assessments are often methodologically complex because diagnostics may not directly, but indirectly, impact outcomes in the entire care pathway. As such, biomarkers require comprehensive models to deal with all possible test– intervention combinations in target patient populations.
Due to high volume and frequent testing, screening, and monitoring tests may trigger budget impact concerns. Diagnosis and prognosis solutions aim to optimize healthcare resource use by improving treatment or more invasive diagnostic decisions.